ZA200303593B - Freeze-dried pantoprazole preparation and pantoprazole injection. - Google Patents
Freeze-dried pantoprazole preparation and pantoprazole injection. Download PDFInfo
- Publication number
- ZA200303593B ZA200303593B ZA200303593A ZA200303593A ZA200303593B ZA 200303593 B ZA200303593 B ZA 200303593B ZA 200303593 A ZA200303593 A ZA 200303593A ZA 200303593 A ZA200303593 A ZA 200303593A ZA 200303593 B ZA200303593 B ZA 200303593B
- Authority
- ZA
- South Africa
- Prior art keywords
- pantoprazole
- salt
- injection
- freeze
- solution
- Prior art date
Links
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 title claims description 42
- 229960005019 pantoprazole Drugs 0.000 title claims description 42
- 229940026447 pantoprazole injection Drugs 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title claims description 9
- 239000000243 solution Substances 0.000 claims description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 19
- 238000002347 injection Methods 0.000 claims description 18
- 239000007924 injection Substances 0.000 claims description 18
- 239000002245 particle Substances 0.000 claims description 17
- 238000004108 freeze drying Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 229940090044 injection Drugs 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 9
- -1 methoxy-2-pyridinyl Chemical group 0.000 claims description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000012906 subvisible particle Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000012538 light obscuration Methods 0.000 claims description 4
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 claims description 4
- 239000002504 physiological saline solution Substances 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims 1
- 239000000047 product Substances 0.000 description 19
- 238000001035 drying Methods 0.000 description 12
- 239000008215 water for injection Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 6
- 238000003756 stirring Methods 0.000 description 5
- 229960001484 edetic acid Drugs 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 229960004048 pantoprazole sodium Drugs 0.000 description 4
- YNWDKZIIWCEDEE-UHFFFAOYSA-N pantoprazole sodium Chemical compound [Na+].COC1=CC=NC(CS(=O)C=2[N-]C3=CC=C(OC(F)F)C=C3N=2)=C1OC YNWDKZIIWCEDEE-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 239000013618 particulate matter Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- JNOJDURFZLCLSX-UHFFFAOYSA-N O.O.O.[Na].[Na] Chemical compound O.O.O.[Na].[Na] JNOJDURFZLCLSX-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 229940001593 sodium carbonate Drugs 0.000 description 2
- IQPSEEYGBUAQFF-SANMLTNESA-N 6-(difluoromethoxy)-2-[(s)-(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical compound COC1=CC=NC(C[S@](=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-SANMLTNESA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- YXLFRKFUVHZXID-UHFFFAOYSA-G [Na+].[Na+].[Na+].C(C)(=O)[O-].C(C)(=O)[O-].C(C)(=O)[O-].C(C)(=O)[O-].C(CN)N.[Na+].[Na+].[Ca+2].C(C)(=O)[O-].C(C)(=O)O.C(C)(=O)[O-].C(C)(=O)[O-].C(CN)N Chemical compound [Na+].[Na+].[Na+].C(C)(=O)[O-].C(C)(=O)[O-].C(C)(=O)[O-].C(C)(=O)[O-].C(CN)N.[Na+].[Na+].[Ca+2].C(C)(=O)[O-].C(C)(=O)O.C(C)(=O)[O-].C(C)(=O)[O-].C(CN)N YXLFRKFUVHZXID-UHFFFAOYSA-G 0.000 description 1
- IRYSNLPWOIOTED-UHFFFAOYSA-N acetic acid ethane-1,2-diamine Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.NCCN.NCCN IRYSNLPWOIOTED-UHFFFAOYSA-N 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- RDRUTBCDIVCMMX-UHFFFAOYSA-N magnesium;5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]benzimidazol-1-ide Chemical compound [Mg+2].COC1=CC=NC(CS(=O)C=2[N-]C3=CC=C(OC(F)F)C=C3N=2)=C1OC.COC1=CC=NC(CS(=O)C=2[N-]C3=CC=C(OC(F)F)C=C3N=2)=C1OC RDRUTBCDIVCMMX-UHFFFAOYSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- FEJQDYXPAQVBCA-UHFFFAOYSA-J tetrasodium;ethane-1,2-diamine;tetraacetate Chemical compound [Na+].[Na+].[Na+].[Na+].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.NCCN FEJQDYXPAQVBCA-UHFFFAOYSA-J 0.000 description 1
- 239000012905 visible particle Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00125569 | 2000-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200303593B true ZA200303593B (en) | 2004-04-23 |
Family
ID=8170452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200303593A ZA200303593B (en) | 2000-11-22 | 2003-05-09 | Freeze-dried pantoprazole preparation and pantoprazole injection. |
Country Status (40)
Country | Link |
---|---|
US (3) | US6780881B2 (es) |
EP (2) | EP1339430B1 (es) |
JP (1) | JP4886158B2 (es) |
KR (2) | KR100910606B1 (es) |
CN (1) | CN1250292C (es) |
AR (2) | AR034277A1 (es) |
AT (1) | ATE381946T1 (es) |
AU (2) | AU2002216042B2 (es) |
BG (1) | BG66329B1 (es) |
BR (1) | BRPI0115483B8 (es) |
CA (2) | CA2541946A1 (es) |
CY (1) | CY1107896T1 (es) |
CZ (1) | CZ304348B6 (es) |
DE (1) | DE60132108T2 (es) |
DK (1) | DK1339430T3 (es) |
EA (1) | EA007602B1 (es) |
EC (1) | ECSP034613A (es) |
EE (1) | EE05236B1 (es) |
ES (1) | ES2298295T3 (es) |
GE (1) | GEP20053461B (es) |
HK (1) | HK1060848A1 (es) |
HR (1) | HRP20030410B1 (es) |
HU (1) | HUP0303278A3 (es) |
IL (2) | IL155601A0 (es) |
IS (1) | IS2971B (es) |
ME (1) | ME00556B (es) |
MX (1) | MXPA03004548A (es) |
MY (1) | MY137726A (es) |
NO (1) | NO332937B1 (es) |
NZ (1) | NZ525911A (es) |
PE (1) | PE20020582A1 (es) |
PL (1) | PL201188B1 (es) |
PT (1) | PT1339430E (es) |
RS (1) | RS52024B (es) |
SI (1) | SI1339430T1 (es) |
SK (1) | SK287993B6 (es) |
TW (1) | TWI284041B (es) |
UA (1) | UA80961C2 (es) |
WO (1) | WO2002041919A1 (es) |
ZA (1) | ZA200303593B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY137726A (en) | 2000-11-22 | 2009-03-31 | Nycomed Gmbh | Freeze-dried pantoprazole preparation and pantoprazole injection |
US20050287231A1 (en) * | 2002-06-21 | 2005-12-29 | Nussen Kenneth H | Method and apparatus for oral hygiene products with green tea extract |
KR20050071611A (ko) * | 2002-10-25 | 2005-07-07 | 화이자 프로덕츠 인코포레이티드 | 현탁액 형태의 아릴헤테로환 활성제의 저장 제형 |
AU2003241150A1 (en) * | 2003-05-06 | 2004-11-26 | Hetero Drugs Limited | Novel polymorphs of pantoprazole sodium |
CL2004000983A1 (es) * | 2003-05-08 | 2005-03-04 | Altana Pharma Ag | Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y |
EP1631284A2 (en) * | 2003-05-19 | 2006-03-08 | Pliva-Istrazivanje I Razvoj D.D.O. | Solid-state forms of 5-(difluoromethoxy)-2-((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole (pantoprazole) sodium aqua complexes |
AR045258A1 (es) * | 2003-08-21 | 2005-10-19 | Altana Pharma Ag | Un producto farmaceutico para inyeccion |
WO2005070426A1 (en) * | 2004-01-27 | 2005-08-04 | Altana Pharma Ag | Freeze-dried (-)-pantoprazole preparation and (-)-pantoprazole injection |
DE102004007854A1 (de) * | 2004-02-17 | 2005-09-01 | Hexal Ag | Stabile, wässrige Formulierung für Benzimidazole |
US20060085924A1 (en) * | 2004-10-13 | 2006-04-27 | Gaelle Brun | Coloring composition comprising at least one pigment and at least one electrophilic cyanoacrylate monomer |
CN1293879C (zh) * | 2005-01-20 | 2007-01-10 | 杭州华东医药集团生物工程研究所有限公司 | 泮托拉唑钠冻干粉针剂及其制备方法 |
JP2009511481A (ja) * | 2005-10-06 | 2009-03-19 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 増強された治療特性を持つ、胃H+,K+−ATPaseの重水素化阻害剤 |
AR061155A1 (es) * | 2006-06-01 | 2008-08-06 | Combino Pharm Sl | Preparaciones liofilizadas de pantoprazol sodico para inyeccion |
EP2049142B2 (en) | 2006-07-26 | 2016-01-20 | Sandoz AG | Caspofungin formulations |
US7979200B2 (en) * | 2006-11-20 | 2011-07-12 | Lockheed Martin Corporation | Managing an air-ground communications network with air traffic control information |
EP2106788A1 (en) * | 2008-04-04 | 2009-10-07 | Ipsen Pharma | Liquid and freeze dried formulations |
CN101744777B (zh) * | 2009-12-30 | 2012-09-26 | 北京四环科宝制药有限公司 | 奥美拉唑钠冻干粉针剂及制备方法和检测方法 |
CN101961309B (zh) * | 2010-09-15 | 2012-06-27 | 河南辅仁怀庆堂制药有限公司 | 注射用泮托拉唑钠配制工艺 |
CN102000034B (zh) * | 2010-10-13 | 2011-12-21 | 江苏奥赛康药业股份有限公司 | 一种供注射用的s-泮托拉唑钠组合物及其制备方法 |
CN102225063B (zh) * | 2011-05-10 | 2012-10-10 | 江苏奥赛康药业股份有限公司 | 一种供注射用的泮托拉唑钠组合物 |
TR201108946A2 (tr) * | 2011-09-12 | 2012-04-24 | World Medicine İlaç Sanayi̇ Ve Ti̇caret Li̇mi̇ted Şi̇rketi̇ | Dondurularak kurutulmuş atp, vitamin b kompleksi preparatı ve enjeksiyonu. |
UY34880A (es) * | 2012-06-27 | 2014-01-31 | Takeda Pharmaceutical | Preparación líquida |
CN104000786A (zh) * | 2013-02-25 | 2014-08-27 | 杭州赛利药物研究所有限公司 | 泮托拉唑钠冻干制剂及其制备方法 |
CN104414979A (zh) * | 2013-08-21 | 2015-03-18 | 哈药集团三精制药股份有限公司 | 一种泮托拉唑钠冻干粉针剂及其制备方法 |
CN104019635B (zh) * | 2014-06-19 | 2015-05-27 | 上海慈瑞医药科技有限公司 | 一种兰索拉唑原料药化合物及其干燥工艺 |
CN104055792A (zh) * | 2014-07-10 | 2014-09-24 | 北京人福军威医药技术开发有限公司 | 西地碘治疗中耳炎的用途 |
CN104055791A (zh) * | 2014-07-10 | 2014-09-24 | 北京人福军威医药技术开发有限公司 | 西地碘治疗眼角结膜炎的用途 |
BE1021311B1 (nl) * | 2014-07-31 | 2015-10-28 | Neogen N.V. | Werkwijze voor het maken van een poedervormige protonpompremmer samenstelling, genoemde samenstelling en gebruik |
US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
CN111643460A (zh) * | 2020-06-30 | 2020-09-11 | 武汉九州钰民医药科技有限公司 | 泮托拉唑钠冻干制剂及其制备方法、由其制得的注射制剂 |
CN112274481A (zh) * | 2020-10-27 | 2021-01-29 | 海南卫康制药(潜山)有限公司 | 一种注射用泮托拉唑钠组合物及其制备方法 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8301182D0 (sv) * | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
IL75400A (en) * | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
US5223515A (en) * | 1988-08-18 | 1993-06-29 | Takeda Chemical Industries, Ltd. | Injectable solution containing a pyridyl methylsulfinylbenzimidazole |
DK399389A (da) | 1988-08-18 | 1990-02-19 | Takeda Chemical Industries Ltd | Injicerbare oploesninger |
DE4035455A1 (de) | 1990-11-08 | 1992-05-14 | Byk Gulden Lomberg Chem Fab | Enantiomerentrennung |
AU674015B2 (en) | 1992-07-28 | 1996-12-05 | Astra Aktiebolag | Injection and injection kit containing omeprazole and its analogs |
WO1994024867A1 (en) * | 1993-04-27 | 1994-11-10 | Sepracor, Inc. | Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole |
DE4324014C2 (de) * | 1993-07-17 | 1995-06-08 | Byk Gulden Lomberg Chem Fab | Verfahren zur Herstellung einer in Wasser rekonstituierbaren Zubereitung |
TW280770B (es) * | 1993-10-15 | 1996-07-11 | Takeda Pharm Industry Co Ltd | |
HU224987B1 (en) | 1995-11-03 | 2006-05-29 | Sanofi Aventis | Stable freeze-dried pharmaceutical formulation |
FR2740686B1 (fr) * | 1995-11-03 | 1998-01-16 | Sanofi Sa | Formulation pharmaceutique lyophilisee stable |
US5980882A (en) | 1997-04-16 | 1999-11-09 | Medeva Pharmaceuticals Manufacturing | Drug-resin complexes stabilized by chelating agents |
DE69835165T2 (de) | 1997-10-14 | 2007-06-06 | Eisai Co., Ltd. | Pharmazeutische Formulierung, die Glycin als Stabilisator umfasst |
DE19843413C1 (de) * | 1998-08-18 | 2000-03-30 | Byk Gulden Lomberg Chem Fab | Neue Salzform von Pantoprazol |
WO2000026185A2 (en) | 1998-10-30 | 2000-05-11 | The Curators Of The University Of Missouri | Omeprazole solution and method of using same |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
CN1235018A (zh) * | 1999-04-22 | 1999-11-17 | 沈阳东宇药业有限公司 | 泮托拉唑钠冻干粉针剂及制备方法 |
SE9903831D0 (sv) * | 1999-10-22 | 1999-10-22 | Astra Ab | Formulation of substituted benzimidazoles |
EP1310252A4 (en) * | 2000-08-18 | 2009-06-10 | Takeda Pharmaceutical | INJECTIONS |
MY137726A (en) * | 2000-11-22 | 2009-03-31 | Nycomed Gmbh | Freeze-dried pantoprazole preparation and pantoprazole injection |
AR045258A1 (es) | 2003-08-21 | 2005-10-19 | Altana Pharma Ag | Un producto farmaceutico para inyeccion |
-
2001
- 2001-10-19 MY MYPI20014865A patent/MY137726A/en unknown
- 2001-11-06 TW TW090127545A patent/TWI284041B/zh not_active IP Right Cessation
- 2001-11-17 WO PCT/EP2001/013296 patent/WO2002041919A1/en active IP Right Grant
- 2001-11-17 EP EP01997314A patent/EP1339430B1/en not_active Revoked
- 2001-11-17 CA CA002541946A patent/CA2541946A1/en not_active Abandoned
- 2001-11-17 ES ES01997314T patent/ES2298295T3/es not_active Expired - Lifetime
- 2001-11-17 GE GE5180A patent/GEP20053461B/en unknown
- 2001-11-17 ME MEP-2008-696A patent/ME00556B/me unknown
- 2001-11-17 IL IL15560101A patent/IL155601A0/xx unknown
- 2001-11-17 AT AT01997314T patent/ATE381946T1/de active
- 2001-11-17 CZ CZ2003-1416A patent/CZ304348B6/cs not_active IP Right Cessation
- 2001-11-17 EA EA200300501A patent/EA007602B1/ru not_active IP Right Cessation
- 2001-11-17 SK SK606-2003A patent/SK287993B6/sk not_active IP Right Cessation
- 2001-11-17 DE DE60132108T patent/DE60132108T2/de not_active Expired - Lifetime
- 2001-11-17 SI SI200130816T patent/SI1339430T1/sl unknown
- 2001-11-17 RS YU37703A patent/RS52024B/sr unknown
- 2001-11-17 EP EP06123558.6A patent/EP1762249A3/en not_active Ceased
- 2001-11-17 HU HU0303278A patent/HUP0303278A3/hu unknown
- 2001-11-17 JP JP2002544096A patent/JP4886158B2/ja not_active Expired - Fee Related
- 2001-11-17 AU AU2002216042A patent/AU2002216042B2/en not_active Expired
- 2001-11-17 PL PL361118A patent/PL201188B1/pl unknown
- 2001-11-17 DK DK01997314T patent/DK1339430T3/da active
- 2001-11-17 BR BRPI0115483A patent/BRPI0115483B8/pt not_active IP Right Cessation
- 2001-11-17 KR KR1020037006675A patent/KR100910606B1/ko active IP Right Grant
- 2001-11-17 AU AU1604202A patent/AU1604202A/xx active Pending
- 2001-11-17 PT PT01997314T patent/PT1339430E/pt unknown
- 2001-11-17 CN CNB01819379XA patent/CN1250292C/zh not_active Expired - Lifetime
- 2001-11-17 NZ NZ525911A patent/NZ525911A/en not_active IP Right Cessation
- 2001-11-17 UA UA20040705223A patent/UA80961C2/uk unknown
- 2001-11-17 EE EEP200300182A patent/EE05236B1/xx not_active IP Right Cessation
- 2001-11-17 CA CA002428870A patent/CA2428870C/en not_active Expired - Lifetime
- 2001-11-17 MX MXPA03004548A patent/MXPA03004548A/es active IP Right Grant
- 2001-11-17 KR KR1020077027736A patent/KR100910607B1/ko active IP Right Grant
- 2001-11-19 PE PE2001001153A patent/PE20020582A1/es active IP Right Grant
- 2001-11-19 AR ARP010105391A patent/AR034277A1/es not_active Application Discontinuation
-
2002
- 2002-07-15 US US10/195,062 patent/US6780881B2/en not_active Expired - Lifetime
-
2003
- 2003-04-28 IL IL155601A patent/IL155601A/en active IP Right Grant
- 2003-05-09 ZA ZA200303593A patent/ZA200303593B/en unknown
- 2003-05-19 EC EC2003004613A patent/ECSP034613A/es unknown
- 2003-05-19 IS IS6820A patent/IS2971B/is unknown
- 2003-05-20 BG BG107828A patent/BG66329B1/bg unknown
- 2003-05-21 NO NO20032303A patent/NO332937B1/no not_active IP Right Cessation
- 2003-05-21 HR HR20030410A patent/HRP20030410B1/xx not_active IP Right Cessation
-
2004
- 2004-05-28 US US10/855,703 patent/US7351723B2/en not_active Expired - Lifetime
- 2004-05-28 HK HK04103845A patent/HK1060848A1/xx not_active IP Right Cessation
-
2008
- 2008-01-22 US US12/010,124 patent/US8754108B2/en not_active Expired - Lifetime
- 2008-02-28 CY CY20081100226T patent/CY1107896T1/el unknown
-
2013
- 2013-08-21 AR ARP130102967A patent/AR092374A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8754108B2 (en) | Freeze-dried pantoprazole preparation and pantoprazole injection | |
AU2002216042A1 (en) | Freeze-dried pantoprazole preparation and pantoprazole injection | |
CA2548074A1 (en) | Injectable composition | |
CA2535813C (en) | Pantoprazole preparation for injection | |
WO2009001163A1 (en) | Lyophilized preparations of pantoprazole sodium for injection | |
AU2006235847B2 (en) | Lyophilized pantoprazole preparation | |
GB2404856A (en) | Stable pharmaceutical composition of rabeprazole |